Daily Newsletter

16 August 2023

Daily Newsletter

16 August 2023

Viz.ai’s hypertrophic cardiomyopathy algorithm gets FDA De Novo approval

Bristol Myers Squibb has provided financial support for the algorithm's implementation.

RanjithKumar Dharma August 16 2023

The US Food and Drug Administration (FDA) has granted De Novo approval for Viz.ai’s hypertrophic cardiomyopathy (HCM) artificial intelligence (AI) detection algorithm, Viz HCM module.

Bristol Myers Squibb provided financial backing for the algorithm's implementation through a multi-year agreement announced in March this year.

By leveraging Viz HCM, which is incorporated into the Viz.ai platform, physicians can identify more individuals with suspected HCM by tapping AI and triaging them for diagnosis and further analysis.

To detect suspected HCM cases and notify cardiologists and care teams through the Viz mobile application, the Viz HCM module automatically reviews routine electrocardiograms (ECGs) from across a health system.

Later, medical professionals can examine the patient's ECG, arrange a follow-up echocardiogram for diagnosis and utilise the Viz Echo Viewer to assess images and obtain echocardiogram reports.

The HCM module stands as one of 12 FDA-approved AI algorithms on the enterprise-wide, clinically validated Viz.ai Platform, according to the company.

The company has also claimed that this platform has demonstrated its capacity to enhance treatment accessibility and boost patient outcomes across over 1,400 hospitals in the US and Europe.

Viz.ai CEO and founder Chris Mansi said: “The ongoing investment of innovative capabilities on our platform is why it continues to be the first choice of leading healthcare systems.

“With our AI-powered Viz HCM module, we look forward to realising its promise in expediting the detection and care of patients with this common, inherited heart disease.”

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close